¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º ?Q0I'RC  
:>+\17tx  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ D`[Khsf  
s@8w-]"  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) ",yc0 2<  
/mA,F;   
1. ICAM-1 CrC =A=e  
Qkcjr]#^$  
2. interleukin 12(IL-12) 6gH{ R$7L=  
`d\r;cE%lm  
3. tumor infiltrating lymphocyte c!#:E`  
oD9^ID+  
4. TCR/CD3 complex H[ m <RaG8  
0[Ht_qxb  
5. hematopoietin receptor family 424(3-/v;  
:Dt~ e|  
6. individual idiotype(IdI) Fv74bC %  
as*4UT3  
7. integrin 8CbXMT  
\C,p WW  
8. colony-stimulatory factor (CSF) \xv;sl$f  
1)m@?CaI`  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© !|ak^GE:(%  
9h&R]yz;  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? #>lG7Ns|4  
JN+_|`  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ 0k)rc$eDF+  
5GA C`}}  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ#7ohQrP  
ljTBvU  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ 86]p#n_>Fv  
CI353-`  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) .L'.c/ s  
Ym3\pRFiD  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ 0lhVqy}:}o  
*98$dQR$  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) phM>.y_  
5[c^TJ3  
3. immunoglobulin superfamily (IgSF) +v=C@2T  
d_IAs  
4. selectin &Z`#cMR{H  
#O+),,WS  
5. anti-idiotypic antibody (¦ÁId) =Xo =Qcr  
J+`VujWT  
6. major histocompatibility complex(MHC) N;\'N ne  
uD^cxD  
7. immunotolerance G K7![p  
V,%=AR5  
8. biological reponse modifier(BRM)  5~>z h  
8uWa=C)  
9. immune reponse gene (Ir gene) 'Iw NTM  
dw*_(ys  
10. reshaped antibody (or reconstituted antibody) INJEsz  
iv4H#rJ  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Eea*s'  
v_DedVhe  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ hpD!2 K3>  
*-8&[D0  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? >&}%+r\  
ivN&HAxI@  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ :gWu9Y|{  
4bYK}o S  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? KV0]m^@x  
xD~5UER  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ 62ws/8d6f  
+[\FD; >  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? ]QlwR'&j/n  
wNpTM8rfU#  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 1cpiHZa  
T?ZRiR)@  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ z`f( $t[  
EVsC >rz  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? #Y a4ps_  
$QN"w L||  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ H4&lb}  
|EX(8y  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: |B.Y6L6l  
<7/R,\Wg~  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: O;:mCt _H  
MOQ*]fV:  
ÃâÒßѧ mwHB(7YS,  
S2sQOM@  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© n|9-KTe7|*  
5\:^ y'g[  
1. CD8 cUKE   
3no%E03p  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) RzE_K'M  
G|!Tj X7s  
3. immunoglobulin fold(Ig fold) }YGV\Nu  
^c"jH'#.L  
4. cadherin (Ca-dependent cell adhesion moleculers) %*A0# F  
Cjm`|~&e+  
5. idiotype-anti-idiotypic antibody immune network theory LDgrR[  
UZ\u;/}  
6. HLA class II antigen _|kxY '_[8  
p& y<I6a,  
7. complementarity-determining region (CDR) 81? hY4  
{f3YsM;]C  
8. perforin(or pore-forming protein ,PFP) Xix L  R  
q;T{|5/O  
9. high affinity IL-2 receptor _mqL8ho  
-`*a'p-=  
10. artificial active immunization O,{6*[)@  
SoW9p^HJ  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© W9 GxXPA  
XRM_x:+]  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠF~R;n_IJ  
#++lg{  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 M8kPj8}{  
\FQRNj?'_  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ l%k\JY-  
`x+ B+)0X  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ ,k +IPkN+  
[\^ n=  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ fx41,0;gZq  
"%`1 ]Fr  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? >:74%D0UF  
Ci@o|Y }tP  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ z`.<U{5  
>{q]&}^U  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ "Gsc;X'id  
5Yg'BkEr  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ %f&/E"M  
7x"R3  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ nHM~  
LA!?H]  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© VACQ+  
Vh'P&W?[  
1. immunoglobulin gene rearrangement aB_F9;IR  
ef 8s<5"4  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) "M<8UE\n  
\ ZgE  
3. flow cytometry(FCM) Gt\lFQ  
1h^:[[!c  
4. carrier effect 0pZ4BZd T|  
=mO vs  
5. positive selection of T lymphocytes in thymus bg!/%[ {M  
hCi60%g/n  
6. mouse TH1(Th1) and TH2(Th2) subsets prWk2_D;*  
{kA0z2Fe  
7. perforin (pore-forming protein ,PFP) /MIe(,>Uh  
qLO4#CKCL6  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) 5VfyU8)7X  
EuEZ D +  
9. SH-2(src-homology region 2) ~Q Oe##  
/fKx} }g)  
10. Ab2¦Â (internal image) 0CWvYC%e  
`XJG(Oas\  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© MR;1 2*p  
TEP,Dq  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? 3$jT*OyG#  
+vw\y  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? Z&G+bdA>,  
Yz'K]M_Dq  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ8Q.T g.  
$By< $  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ M-$%Rzl_  
^6jV_QM#  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠIDad9 Bx  
vt/x ,Y  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) C1V|0h u  
Ja|5 @  
ÃâÒßѧרҵ£º Rm2yPuOU}A  
b10cuy|a/X  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ '@a}H9>}  
ZAW^/bo<  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? $r^GE  
kC:uG0sW  
´«È¾²¡Ñ§×¨Òµ£º C>]0YO k2  
55G+;  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ <KJ/<0l  
gl~ecc  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ rbul8(1h  
aJSO4W)P  
Ïû»¯×¨Òµ£º 'HO$C, 1]  
KsddA  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ Mhm@R@  
|+{)_?  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? M5i%jZk  
mJ<=n?{Z  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ af6M,{F  
\0A3]l  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© se ba9 y  
?)/#+[xa  
1. Fas(CD95)/FasL O8f?; ]  
M +-*QyCFK  
2. common chain of cytokine receptor <3L5"77G 6  
)i6mzzj5  
3 . TCR/CD3 complex )"qa kT  
)tG\vk=@  
4. negaive selection of thymocytes *=) cQeJ  
} F E>|1  
5. artificial active immune 2L!u1  
$5 >e  
6. anti-idiotypic 1eA7>$w}[  
j*d yp  
7. IgSF CMe 06^U   
4"GR] X  
8. Integrin Ig $(3p  
\-L&5x"x  
9. chemokine W=lyIb{?^0  
@efh{  
10. B7/CD28 Y=%tn8<  
w?3p';C  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© zy?.u.4L  
$yN{-T"  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ 'QJ:`)z  
5]~'_V  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ s:?SF.  
Y)1PB+  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ Ha(c'\T (\  
j >Ht@Wi  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ @#<D ^"  
%}[i'rT>  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ Jlri*q"hE  
oxC[F*mD  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ V n7*JS  
\}+_Fo/  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©  R(!s  
t=rEt>n~L  
1. B7/CD28 Olt `:;j-  
t 4PK}>QW  
2. Th1 subset .O74V~T  
r/4``shg  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© wZG\>9~  
ccNd'2P  
4. antibody affinity maturation _?<|{O  
^.1)};i  
5. AP-1  0bz'&  
KmMzH`t}`  
6. single chain variable fragment£¨ScFv£© RdWRWxTn8+  
u_hD}V^x4  
7. NK cell receptor .GV;+8HzS  
^2+yHw  
8. Zinkernagel-Doherty phenomenon .+qQYDE w  
 RwKdxK+;  
9. Ig fold 05z,b]>l  
t'VV>;-RO=  
10. CD40/CD40L !i{aMxUP  
W6f/T3  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© H+1-]'g`  
9G9fDG#F\I  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ 6 2'j!"xv  
->sm+H-*  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ 9zZr^{lUl  
)+l\w3^6  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ [ OM7g'?S0  
\wo?47+=  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ 0>C T=(A  
,#Iu 7di  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ yGWxpzmRS  
cU;iUf  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ F=`AY^u0  
C3eR)Yh  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ u6T+Cg  
(}a8"]Z  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© vu|n<  
lV`Q{bd+  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© #OIcLEn%  
s8-<m,*  
1.Co-stimulators (or co-stimulating molecules) KB%"bqB|  
Ey_" ~OB  
2.NK-kB /]=C{)8  
)Gj8X}DM  
3.Immunoglobulin superfamily b vS(@  
qDv9 3  
4.antigen-presenting cell (APC) 8)O[Aq::  
=; ^%(%Y{m  
5.death domain z8QAo\_I(  
, 8:(OB|a  
6.CCR and CXCR U'8bdsF_  
Qj,]N@7  
7.Lectin (or mitogen) hCCiD9gz  
p89wNSMl[  
8.Clusters of differentiation, CD) WKT4D}{1  
YQ39 A_e g  
9.B7 family . C&ktU4  
*"D3E7AO  
10.Cytotoxic T lymphocyte, CTL) 4G$|Rx[{,  
^~G8?]w  
11.IL-15 and IL-15 receptor (IL-15R) MP_'D+LS  
F_;vO%}  
12.MHC restriction zoOaVV&1  
!OBEM1~ 1  
13.Affinity-chromatography !'mq ?C=  
%;e/7`>Ma  
14.Cyctosprin A, CsA >Y #t`6,!  
 #tZ4N7  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) $4tWI O  
BB~OqZIP  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© ]T;EdK-  
*tgnYa[l  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 D+]a.& {p  
TQx.KM>y  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ b!sRk@LGZ  
4F {)i  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ >S'17D  
6`v7c!7  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© bzX\IrJpOZ  
q~3,yyu  
ÃâÒßѧרҵ£º E-I-0h 2  
<5NF;  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ m|=H#  
_io+YzS  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ q|Qk2M  
=Qgt${|  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ H63,bNS s  
\T <$9aNb  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) 0&/b42W  
+"8,Mh  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) 91$]Qg,lB  
:{oZ~<  
1. ADCC(antibody dependent cell-mediated cytotoxicity) rk7QZVE  
n84GZ5O>7  
2. »·æß¾úËØ(cyclosporin) U7I qST  
< V\I~;  
3. KIR(killer cell inhibitory receptor) !zPa_`P  
>2]JXLq  
4. HLDA(human leucocyte differentiation antigen) #*TEq  
s 1e:v+B]  
5. Interleukin 18(IL-18) nzmDA6d  
2Sh  
6. ÕûºÏËØ(integrin) h}]fn A  
7DIIx}A  
7. Fas/FasL [+OnV&  
v{9t]s>B  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) C&6IU8l\  
}J7zTj~{  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) om]4BRe  
r\blyWi  
10. Th1/Th2 04*6(L)h*  
S6fL>'uQ  
11. »ùÒòÒßÃç(DNAÒßÃç) z^GDJddG  
H6&J;yT}  
12. chemokines and chemokine receptor \TF!S"V  
3q`)*  
13. ÃâÒßÄÍÊÜ P1NJ^rX  
4WE6fJ2X  
14. ¹²´Ì¼¤·Ö×Ó Dc+'<"  
r YF #^  
15. ËÀÍö½á¹¹Óò(death domain) ?_ dIIQ  
+Y V|ij  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) m~dC3}e8/?  
TARXx>  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? ]XTu+T.aT  
;/0 Q1-  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠe#B#B  
qVdwfT{1J  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î UK{irU|\  
m ~>Y{F2  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ #BQ.R,  
8kbY+W%n  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå {<5ybbhLV  
Q0\0f  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ o=RM-tR`v  
8v7 1e>  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) LPwT^zV&N  
fl;s9:<  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ 0[F:'_  
-!)xQvagD.  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ gt\MS;jMa  
.@"q$\  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»